Abstract
Aim:
The study aim was to evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal cell carcinoma on sunitinib (SU) and SU-everolimus treatment.
Patients & methods:
After 7 years of enrollment and 9 years of follow-up, 193 consecutively presenting patients (151 men and 42 women) were treated.
Results:
A total of 157 patients (81.3%) died and 36 patients (18.7%) survived. Median PFS in 193 SU-treated patients was 14.7 months and OS was 28.8 months. Median PFS was 13.98 months and median OS was 26.67 months in 175 patients treated with SU only or on SU-everolimus.
Conclusion:
The development of SU-induced hypothyroidism, hypertension, neutropenia and edema was a significant predictive and prognostic factor.
Keywords:
EVE; SU; everolimus; prediction; prognosis; renal cancer; sunitinib; survival.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / pathology*
-
Combined Modality Therapy
-
Everolimus / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects
-
Indoles / therapeutic use*
-
Kaplan-Meier Estimate
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology*
-
Male
-
Middle Aged
-
Proportional Hazards Models
-
Pyrroles / administration & dosage
-
Pyrroles / adverse effects
-
Pyrroles / therapeutic use*
-
Retreatment
-
Risk Factors
-
Sunitinib
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Indoles
-
Pyrroles
-
Everolimus
-
Sunitinib